Earl, H. M., Hiller, L., Dunn, J. A., Vallier, A., Bowden, S. J., Jordan, S. D., . . . Poole, C. J. (2012). Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: Results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Nature Publishing Group.
Chicago-стиль цитированияEarl, H M., et al. Adjuvant Epirubicin Followed By Cyclophosphamide, Methotrexate and Fluorouracil (CMF) Vs CMF in Early Breast Cancer: Results With Over 7 Years Median Follow-up From the Randomised Phase III NEAT/BR9601 Trials. Nature Publishing Group, 2012.
MLA-цитированиеEarl, H M., et al. Adjuvant Epirubicin Followed By Cyclophosphamide, Methotrexate and Fluorouracil (CMF) Vs CMF in Early Breast Cancer: Results With Over 7 Years Median Follow-up From the Randomised Phase III NEAT/BR9601 Trials. Nature Publishing Group, 2012.